why choose us

First received: January 03, 2023

Clinical Trial: Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

Study Status: Completed

Recruit Status: RECRUITING

Condition: Alzheimer Disease

Study Type: OBSERVATIONAL


Official Title: Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

Brief Summary: The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.The investigators will first complete whole-body PET dosimetry studies in healthy adult normal volunteers to calculate the actual radiation dose of each human organ and determine the allowable dose for a human subject when receiving a single dose for a PET scan.Second, imaging of the brain and neck will be completed in a wide range of ages of healthy adult normal control…

Read more